drugset / Trial / NCT03172884
Study of Copanlisib in Hepatic or Renal Impairment
Non-randomizedParallel-groupOpen-labelOther
Summary
To evaluate the pharmacokinetics and safety of copanlisib in subjects with impaired hepatic or renal function in comparison to healthy subjects
Timeline
- Start
- 2017-06-14
- Primary completion
- 2020-03-13
- Completion
- 2020-05-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Copanlisib | Small molecule | 12 mg | Intravenous |